Skip to main content
. 2014 May 26;8(2):789–794. doi: 10.3892/ol.2014.2177

Table IV.

Frequencies of Axin2 SNP genotypes (GG, GA or AA) and alleles (G or A) and the adjusted OR stratified by the aggressiveness of the cancer, for controls (n=100) versus patients (n=35) with localized PCa, and for controls (n=100) versus patients with advanced PCa (n=68).

Genotype or allele Controls, n (%) Localized PCa, n (%) Adjusted ORa (95% CI) P-value Controls, n (%) Advanced PCa, n (%) Adjusted ORa (95% CI) P-value
GG 39 (39.0) 24 (68.6) 1.00 (Reference) 39 (39.0) 37 (54.4) 1.00 (Reference)
GA 52 (52.0) 9 (25.7) 0.25 (0.10–0.61) 0.002 52 (52.0) 22 (32.4) 0.45 (0.23–0.87) 0.018
AA 9 (9.0) 2 (5.7) 0.38 (0.07–1.98) 0.249 9 (9.0) 9 (13.2) 1.06 (0.37–3.02) 0.921
non-GG 61 (61.0) 11 (31.4) 0.26 (0.11–0.62) 0.002 61 (61.0) 31 (45.6) 0.53 (0.28–0.99) 0.048
G 130 (65.0) 57 (81.4) 1.00 (Reference) 130 (65.0) 96 (70.6) 1.00 (Reference)
A 70 (35.0) 13 (18.6) 0.41 (0.21–0.81) 0.010 70 (35.0) 40 (29.4) 0.67 (0.39–1.13) 0.133
a

Adjusted for age, smoking status and drinking status in a logistic regression model.

SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; PCa, prostate cancer.